Select region:

Clinical trials located in

Aachen

Aachen city is located in Germany. Currently, 20 clinical trials are being conducted in this city.

Aachen, located in western Germany near the borders with Belgium and the Netherlands, is renowned for its rich history and architectural marvels. The city’s centerpiece, Aachen Cathedral, is a UNESCO World Heritage site, famous for being the oldest cathedral in northern Europe and for holding the throne of Charlemagne, one of Europe’s most significant historical figures. Aachen is also known for its thermal springs, which have been attracting visitors since Roman times. The city played a pivotal role in the Carolingian Renaissance, a period marked by a revival of art, culture, and learning under Charlemagne’s reign.

  • CT-EU-00026648

    Iptacopan as a new hope for the treatment of paroxysmal nocturnal hemoglobinuria

    In this phase 3 trial, iptacopan’s efficacy and safety are assessed in adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) who switch from standard anti-C5 treatments to iptacopan. The study, involving multiple centers, consists of an initial 8-week screening and a subsequent 24-week treatment phase with iptacopan. The primary focus is to determine if iptacopan can effectively manage PNH while maintaining patient safety. Participants showing benefits from iptacopan after the treatment period have the opportunity to continue in a roll-over extension study, allowing further observation of iptacopan’s long-term impacts.

    FranceGermanyItalySpainUnited Kingdom
  • New therapy trial for relapsed large B-cell lymphoma

    This study is testing the use of two different treatments for diffuse large B-cell lymphoma (DLBCL), a type of blood cancer. Group One receives a mix of drugs, including polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide (collectively called Pola-R-ICE). Group Two receives a similar mix without polatuzumab vedotin, known as R-ICE. Patients will be randomly sorted into the two groups. The test treatment spans three months and includes three chemotherapy treatments. After that, doctors will follow up with patients for at least 21 months. The goal is to compare how well the two treatments work to control DLBCL. Different factors, like progress of the disease, the response to treatment, and overall health will be observed to determine how efficient these treatments are.

    AustriaGermanySpainUnited Kingdom
  • Evaluating durvalumab in small cell lung cancer treatment

    This study examines the effectiveness and safety of adding durvalumab to standard radiochemotherapy for patients with limited-stage small cell lung cancer (SCLC). It’s an open-label trial where patients are randomly divided into two groups. One group receives durvalumab in combination with standard therapy, while the other receives only standard therapy. The primary goal is to assess how well the combination therapy works in preventing cancer progression, with a focus on patient survival and response to treatment.

    Germany
  • Study on solnatide’s effect on acute respiratory distress syndrome

    The study aims to assess a new medication, Solnatide, for individuals with a severe lung condition known as ARDS (Acute Respiratory Distress Syndrome), which results in fluid accumulation in the lungs. Participants will inhale varying amounts of Solnatide over a one-week period, and their response to the medication will be closely monitored. The primary objectives are to confirm the safety of the medicine and evaluate its potential benefits for these patients. Safety assessments will involve monitoring for side effects and adverse health events. Additionally, medical tests will be conducted to measure the level of fluid in the lungs and assess the impact of the drug on participants’ breathing. The results of this study will play a crucial role in determining the broader applicability of Solnatide in the future.

    AustriaGermany
  • Understanding the effects of tominersen on early-stage Huntington’s Disease

    This clinical trial focuses on evaluating the investigational drug, tominersen, in people in the early stages of Huntington’s disease-a genetic disorder characterised by the progressive breakdown of nerve cells in the brain. This study aims to understand the potential of tominersen to slow the progression of the disease and improve quality of life by administering different doses or placebo directly into the spinal cord to target the areas of the brain most affected by the disease. Participants’ health status will be rigorously monitored and a series of assessments will be conducted to track changes in motor function, cognitive abilities and emotional wellbeing. Additionally, the study will measure specific biomarkers to assess the biological impact of treatment, offering valuable information for tailoring future therapies. This study represents an important opportunity to better understand Huntington’s disease and explore effective treatment options.

    AustriaDenmarkFranceGermanyItalyPolandPortugalSpainUnited Kingdom
  • Study on new drug effects in treating blood disorder

    In this study, the drug being investigated is INCA033989. It will be given alone or in combination with ruxolitinib in people with excess blood cells, a condition known as myeloproliferative neoplasms. The primary goal of the research is to assess safety, comfort and the occurrence of possible harmful effects, especially at specific dosages. Additionally, doctors will try to determine the highest dose participants can tolerate without serious side effects. Importantly, observations will be made regarding any changes in the disease or participants’ subjective experiences.

    DenmarkFranceGermanyItalySpainUnited Kingdom
  • Examining ultrasound-assisted and standard treatment for lung clots

    In this study, researchers want to compare two treatments for a disease called pulmonary embolism. This is a disease in which a blood clot blocks the vessels that supply blood to the lungs. The group of people taking part in the study will be randomly assigned to receive either blood-thinning medications alone (anticoagulation) or blood-thinning medications using a blood clot-dissolving device. The name of this device is the EkoSonic endovascular device. The research will continue for 12 months, and the health of the participants will be regularly monitored.

    AustriaFranceGermanyNetherlandsPolandUnited Kingdom
  • Study testing Ruxolitinib cream for Prurigo Nodularis treatment

    This study is testing a cream with Ruxolitinib to see if it’s safe and effective for people with a skin condition called Prurigo Nodularis (PN). The study has three main parts. In the first 12 weeks, participants will receive either the cream with Ruxolitinib or placebo (also known as vehicle-controlled) treatment. After that, all participants will receive the cream with Ruxolitinib for another 40 weeks. After that, there will be an extra 30 days to keep an eye on safety. The trial will measure success by checking if the cream can reduce itchiness. Treatment success will be evaluated by medical professionals, considering factors such as the number of skin nodules and the extent of redness and crusting in the condition’s severity.

    BelgiumFranceGermanyItalyNetherlandsPolandSpain
  • Testing ustekinumab treatment for severe ulcerative colitis

    This clinical trial is focused on understanding the safety and effectiveness of a medication named Ustekinumab in children and adolescents who are experiencing moderate to severe Ulcerative Colitis (UC), a type of inflammatory bowel disease that causes long-lasting inflammation and ulcers in the digestive tract. The study administers Ustekinumab initially through an IV (intravenous infusion) and then as a subcutaneous injection. The main aims are to determine whether Ustekinumab can help these young patients achieve clinical remission, meaning their UC symptoms are reduced or completely go away, and to monitor how the drug behaves in their bodies. Throughout the trial, the health and safety of the participants are closely monitored.

    BelgiumGermanyHungaryPolandUnited Kingdom
  • Pemigatinib in the treatment of cholangiocarcinoma

    This study focuses on comparing the impact and safety of two treatments: Pemigatinib and a chemotherapeutic combination of Gemcitabine and Cisplatin. These treatments are being tested on people who have an advanced form of liver cancer, cholangiocarcinoma, which cannot be removed by surgery or has spread to other parts of the body, and is associated with a particular genetic change known as FGFR2 rearrangement. The aim is to examine the effectiveness of Pemigatinib in comparison to the chemotherapy combination of Gemcitabine and Cisplatin. Measurements of success will be based on how much the cancer shrinks, the duration of response to treatment, as well as any side effects encountered.

    AustriaBelgiumFranceGermanyItalyNetherlandsSpainSwedenUnited Kingdom
  • Evaluating different drugs for advanced multiple myeloma

    This study is conducted to see how good a medication called Elranatamab is for individuals having multiple myeloma, a blood cancer that affects the marrow inside your bones. This study will use Elranatamab alone, or pair it with another medication called Daratumumab. The aim is to see if Elranatamab alone or mixed with Daratumumab is better than the current treatment of Daratumumab mixed with two other medications named Pomalidomide and Dexamethasone. This research is primarily for individuals who have undergone previous treatments with medications, Lenalidomide and a proteasome inhibitor. The study has two parts. The aim of the first part is the safety test and effects of Elranatamab mixed with Daratumumab at various doses. The second part will divide participants into three groups: Elranatamab alone, Elranatamab with Daratumumab, or the current treatment. The goal is to observe which treatment is safer and works better.

    AustriaCzechiaFranceGermanyGreeceItalyPolandSpainSwedenUnited Kingdom
  • Monitoring the long-term safety of Nivolumab for cancer survivors

    This study is designed to understand the long-term effects of a medicine called Nivolumab in patients who have fought against various forms of cancer. In this study, the focus is on closely examining the long-term efficiency and safety of Nivolumab. Participants in the investigation encompass both current and past users of Nivolumab.

    AustriaBelgiumCzechiaFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSpainUnited Kingdom
  • Testing Milvexian’s effectiveness in preventing repeat strokes

    This research trial, called LIBREXIA-STROKE, will test a medication called Milvexian on those who have recently had a stroke or a high-risk ‘mini-stroke’. In its 3rd testing phase, the study will involve a system where the patients won’t know whether they are receiving the actual drug or a substitute with no effect, referred to as a ‘placebo’, to maintain fairness. Milvexian is a medication that can potentially reduce the risk of having another stroke, and this trial aims to observe how effective it is in doing so. The trial will look at when the first stroke happens after starting the trial, if other major heart or limb diseases occur, or if strokes occur in the first 90 days.

    AustriaBelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainSwedenUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Assessing olpasiran treatment for heart disease and elevated cholesterol

    Tests named ‘OCEAN(a)’ are being conducted, focusing on a medication called ‘olpasiran’. Put simply, the potential of this medication in preventing serious heart episodes in individuals with Atherosclerotic Cardiovascular Disease and an elevated level of a fat protein, Lipoprotein(a), is under examination. The effect of a harmless, dummy pill (placebo) is compared to that of the actual medication, olpasiran, in individuals with these conditions. The primary goal is to determine whether olpasiran can reduce the risk of death due to heart disease, occurrence of heart attacks, or the necessity for sudden surgery to clear blocked heart vessels.

    AustriaBelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSlovakiaSpainSwedenUnited Kingdom
  • Examining Octaplex’s effect on stopping acute bleeding in patients on blood-thinning drugs

    This is a detailed study that aims to test the efficiency and safety of a medication called OCTAPLEX. The medication is used for patients who are having severe bleeding, and are already on a type of medication known as Factor Xa Inhibitor. Patients will be split into two groups and will receive the medication in either a high or low dosage. The study will observe the participants for 30 days to see how well their bodies are proceeding with preventing the bleeding. They will also be studying various health factors such as body temperature, pulse, breathing rate, and blood pressure.

    AustriaGermanyItalyPolandSpainUnited Kingdom
  • Testing the safety and efficiency of elenestinib in mastocytosis patients

    This study evaluates the drug BLU-263 plus supportive care versus placebo in patients with Indolent Systemic Mastocytosis (ISM), a condition where mast cells accumulate in body tissues. It aims to see if BLU-263 can better control symptoms than standard treatments. The study has several parts, enrolling patients with ISM and some with monoclonal mast cell activation syndrome (mMCAS). The main focus is the drug’s effectiveness and safety in managing ISM symptoms.

    AustriaBelgiumFranceGermanyItalyNetherlandsNorwayPortugalSpainUnited Kingdom
  • Examining the safety and effectiveness of fazirsiran in people with liver disease due to certain protein abnormality

    This study is looking into a medication called fazirsiran. It is being tested to see if it can help people who have liver disease due to a faulty version of a protein called Alpha-1 Antitrypsin. The researchers want to see if fazirsiran can reduce scarring in the liver and slow down the disease. They will also study how fazirsiran interacts with the body and if it can lower levels of liver inflammation and of the faulty protein. Participants in this study will either get fazirsiran or a placebo (a treatment with no active ingredients). Two liver biopsies will be performed to remove small amounts of liver tissue for examination. Researchers will check for changes in scarring, inflammation, proteins in the liver, and liver stiffness.

    AustriaBelgiumFranceGermanyItalyPolandPortugalSpainUnited Kingdom
  • Study of Belcesiran’s effect in alpha-1 antitrypsin deficiency liver disease

    This study is about a new drug named Belcesiran. It’s being tested on adults who have a problem with their liver because of a disease called AATLD (Alpha-1 Antitrypsin Deficiency-associated Liver Disease). The drug will be given to three separate groups of patients. There will be no more than 16 patients in the first two groups, and about 30 patients in the third group. Each group will have different ways of taking the medicine, with some differences in things like how long they get the treatment, how many doses they take, and when they get a second liver checkup.The aim is to find out if Belcesiran is safe to take, how patients react to it, and what it does in the body and to the disease.

    AustriaBelgiumFranceGermanyNetherlandsPortugalSpainSwedenUnited Kingdom

See more clinical trials in other cities in Germany:

.